1. Home
  2. People

Elaine Binkley, MD

Associate Professor of Ophthalmology and Visual Sciences

Current Positions

  • Associate Professor of Ophthalmology and Visual Sciences

Education

  • Resident in Ophthalmology, The Ohio State University, Wexner Medical Center, Columbus, OH
  • Fellow in Vitreoretinal Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA
  • Fellow in Retina Clinical and Molecular Research, University of Iowa Hospitals & Clinics, Iowa City, IA
  • Visiting Scholar in Ocular Oncology, Cleveland Clinic, Cleveland, OH

Research Interests

  • Prognostication in posterior uveal melanoma
  • Optimization of brachytherapy treatment for posterior uveal melanoma
  • Pathophysiology and treatment of radiation retinopathy
  • Clinical and molecular pathophysiology of von Hippel-Lindau disease
  • Ocular side effects of systemic chemotherapeutic agents
  • Molecular pathophysiology of ocular disease in neurofibromatosis type 1
  • I study more rare intra-ocular tumors with a special interest in von Hippel-Lindau (VHL) disease and neurofibromatosis. I study the mechanisms behind phenotypic variability in VHL disease and potential molecular treatment approaches and was a co-primary investigator on a R21 grant funded project studying this topic. I am the co-primary investigator on a project grant funded by the Gilbert Family Foundation studying the molecular pathophysiology of neurofibromatosis and novel treatment approaches. I also participate in studies of primary vitreoretinal lymphoma, choroidal metastasis, and retinoblastoma
  • I collaborate with the Holden cancer center as part of clinical trials of novel targeted therapies for systemic malignancies and study the mechanisms behind ocular side effects of systemic chemotherapeutic medications

Licenses & Certifications

  • Certified EDIC Ophthalmologist (Epidemiology of Diabetes Interventions and Complications Trial)

Selected Publications

  • Kaliki S, Vempuluru VS, Fabian ID; Global Retinoblastoma Study Group. (2024). Retinoblastoma with and without Extraocular Tumor Extension: A Global Comparative Study of 3435 Patients. Ophthalmol Sci 5(2):100637. DOI: 10.1016/j.xops.2024.100637. PMID: 39758129. PMCID: PMC11696820.
  • Evbuomwan M, Uzomah U, Anderson C, Boldt HC, Binkley E. (2024). Choroidal metastasis in the systemic targeted therapy era. International Journal of Radiation Oncology 120(2)supplement:E751. ASTRO meeting Washington, DC.
  • Lozano L, Stone E, Mullins R, Tucker B, Binkley E. (2024). Developing a molecular assay to predict hemangioblastoma phenotype severity in VHL disease. ARVO, Seattle, WA.
  • Binkley E, Lozano L, Pham C, Menke J, Syed N, Boldt HC. (2024). Pigmented choroidal schwannoma mimicking choroidal melanoma. Presented at the International Society for Ocular Oncology Virtual meeting.
  • Ahmad N, Goldstein A, Syed N, Binkley E. A Case of Uveal Effusion Syndrome. Women in Ophthalmology meeting.
  • Boldt HC, Binkley E, King BA, Pennington E, Hyer D, Javed A, Milhem M, Hinz C, Mott S. (2023). Post-operative echography for optimization of radiation dosimetry in patients with posterior uveal melanoma treated with I-125 brachytherapy. Macula Society, Miami, FL.
  • Bowen RC, Lozano LP, Boldt HC, Tucker MA, Binkley EM. (2022). Grading ocular disease severity in patients with von Hippel-Lindau disease. International Society for Ocular Oncology Meeting, Leiden, Netherlands.
  • Raval V, Singh A, Binkley E, Aronow M, Valenzuela J, Peereboom D. (2022). Primary central nervous system lymphoma: inter-compartmental progression. International Society for Ocular Oncology Meeting, Leiden, Netherlands.
  • Binkley EM, King BA, Pennington E, Boldt HC. (2019). Post-operative echography for optimization of radiation dosimetry in patients with posterior uveal melanoma treated with plaque brachytherapy. International Society for Ocular Oncology Meeting, Leiden, Netherlands
  • Bellerive C, Binkley E, Singh A. (2019). Class 2 gene expression profile of a hemorrhagic pigment epithelial detachment misdiagnosed as melanoma. International Society of Ocular Oncology Conference, Los Angeles, CA.